

CITATION REPORT

List of articles citing

PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study

DOI: 10.1161/circheartfailure.110.944694
Circulation: Heart Failure, 2011, 4, 8-17.

Source: <https://exaly.com/paper-pdf/51944913/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
343	Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. 2011 , 11, 287-94		64
342	Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure. 2011 , 45, 1551-8		11
341	Phosphodiesterases and cardiac cGMP: evolving roles and controversies. 2011 , 32, 360-5		73
340	Novel therapeutic targets for the treatment of heart failure. 2011 , 10, 536-55		99
339	Medical therapy for chronic heart failure. 2011 , 378, 713-21		64
338	PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study. 2011 , 2011, 323-325		
337	Recent progress in the management of pulmonary hypertension. 2011 , 75, 1801-10		65
336	Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. 2011 , 10, 111-26		254
335	Pulmonary hypertension and right ventricular function in advanced heart failure. 2011 , 17, 189-98		24
334	Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010). 2011 , 21, 1631-41		19
333	Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence. 2011 , 8, 219-25		2
332	Benefits of PDE5 inhibition in patients with diastolic heart failure. 2011 , 11,		78
331	Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. 2011 , 124, 164-74		399
330	Res-erection of Viagra as a heart drug. <i>Circulation: Heart Failure</i> , 2011 , 4, 2-4	7.6	6
329	Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. <i>Circulation: Heart Failure</i> , 2011 , 4, 276-85	7.6	122
328	sGC α 1 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handling. 2011 , 301, H157-63		25
327	Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. 2011 , 123, 1185-93		220

326	Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects. 2012 , 44, 766-75		22
325	Circulation Editors' Picks. 2012 , 126,		
324	Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. 2012 , 125, 2353-62		47
323	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. 2012 , 33, 1787-847		3691
322	Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. 2012 , 126, 830-9		306
321	Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. <i>Circulation: Heart Failure</i> , 2012 , 5, 653-9	7.6	98
320	Pulmonary hypertension and right ventricular failure in left ventricular systolic dysfunction. 2012 , 27, 262-72		13
319	Can adult heart failure regimens be applied to children: what works and what does not?. 2012 , 27, 98-107		4
318	Circulation: Heart Failure Editors' Picks. <i>Circulation: Heart Failure</i> , 2012 , 5,	7.6	
317	Is inhibition of phosphodiesterase type 5 by sildenafil a promising therapy for volume-overload heart failure?. 2012 , 125, 1341-3		7
316	Differential expression of PDE5 in failing and nonfailing human myocardium. <i>Circulation: Heart Failure</i> , 2012 , 5, 79-86	7.6	60
315	Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. 2012 , 126, 942-51		29
314	Circulation: Heart Failure Editors' Picks. <i>Circulation: Heart Failure</i> , 2012 , 5,	7.6	2
313	Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure. <i>European Journal of Heart Failure</i> , 2012 , 14, 1104-1113		11
312	Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. 2012 , 125, 2323-33		129
311	Heart failure: a PKG- α balancing act. 2012 , 126, 797-9		3
310	Circulation: Heart Failure Editors' Picks. 2012 , 126,		
309	Protein kinase G α inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. <i>Journal of the American Heart Association</i> , 2012 , 1, e003731	6	54

308	Heart failure: not just the heart but also the lungs. 2012 , 5, 689-90		
307	PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update. 2012 , 18, 5590-606	14	
306	Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study. 2012 , 2012, 340-342		1
305	Phosphodiesterases and cyclic GMP regulation in heart muscle. 2012 , 27, 248-58		38
304	Cyclic GMP-dependent signaling in cardiac myocytes. 2012 , 76, 1819-25		82
303	Pulmonary hypertension due to left heart disease. 2012 , 126, 975-90		294
302	The future of heart transplantation. 2012 , 12, 2875-91		24
301	Molecular and cellular basis for diastolic dysfunction. 2012 , 9, 293-302		77
300	Diastolic heart failure: What we still don't know. Looking for new concepts, diagnostic approaches, and the role of comorbidities. 2012 , 37, 875-9		25
299	Nitric oxide modulation as a therapeutic strategy in heart failure. 2012 , 8, 255-72		11
298	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2012 , 14, 803-69	12.3	1892
297	[Heart failure with preserved ejection fraction: a systemic disorder?]. 2012 , 33, 370-80		5
296	Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling. 2012 , 52, 330-40		76
295	Reverse remodeling in heart failure--mechanisms and therapeutic opportunities. 2011 , 9, 147-57		152
294	The year in heart failure. 2012 , 60, 359-68		11
293	Pulmonary hypertension associated with left-sided heart disease. 2012 , 8, 447-59		24
292	Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. 2012 , 9, 192-9		26
291	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. 2012 , 65, 938.e1-938.e59		27

290	Mensagem do Editor. <i>Arquivos Brasileiros De Cardiologia</i> , 2012 , 99, 575-575	1.2	1
289	Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. 2012 , 33, 689-96		65
288	Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. 2012 , 165, 1288-305		224
287	Developments in heart failure 2011. 2012 , 18, 112-26		1
286	The malignant obesity hypoventilation syndrome (MOHS). 2012 , 13, 902-9		18
285	ULTIMATE-SHF trial (Udenafil Therapy to Improve symptoMATology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial. 2013 , 14, 188		7
284	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. 2013 , 62, 1495-1539		233
283	The role of B-type natriuretic Peptide testing in guiding outpatient heart failure treatment. 2013 , 15, 397-409		1
282	Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. 2013 , 10, 26-35		14
281	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 2013 , 128, e240-327		1927
280	Right ventricular afterload and the role of nitric oxide metabolism in left-sided heart failure. 2013 , 19, 712-21		14
279	Pharmacotherapy of Pulmonary Hypertension. <i>Handbook of Experimental Pharmacology</i> , 2013 ,	3.2	2
278	Heart failure: what does ejection fraction have to do with it?. 2013 , 62, 1-3		19
277	Pathological ventricular remodeling: therapies: part 2 of 2. 2013 , 128, 1021-30		103
276	Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension. 2013 , 69, 2027-36		11
275	Nitric oxide synthases in heart failure. 2013 , 18, 1078-99		112
274	Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research. <i>Circulation: Heart Failure</i> , 2013 , 6, 584-93	7.6	22
273	Right atrial volume and phasic function in pulmonary hypertension. 2013 , 168, 420-6		40

272	Recomendações de 2012 da ESC para o diagnóstico e o tratamento da insuficiência cardíaca aguda e crónica. 2013 , 32, 641.e1-641.e61		
271	Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. 2013 , 309, 1268-77	762	
270	Heart failure. 2013 , 1, 1-20	481	
269	Fontan circulation: success or failure?. 2013 , 29, 811-20	55	
268	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 , 62, e147-239	4318	
267	A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. 2013 , 62, 263-71	1791	
266	Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. 2013 , 34, 1233-44	70	
265	Therapeutic potential of PDE modulation in treating heart disease. 2013 , 5, 1607-20	24	
264	Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHILD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial. 2013 , 3, 889-97	8	
263	Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?. 2013 , 2013, 130724	11	
262	[Recent and future innovations in the treatment of heart failure]. 2013 , 13, 266-74		
261	Contemporary management of tricuspid regurgitation: an updated clinical review. 2013 , 21, 174-83	6	
260	Heart failure with preserved ejection fraction: emerging drug strategies. 2013 , 62, 13-21	39	
259	The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. <i>Journal of the American Heart Association</i> , 2013 , 2, e000536	6	82
258	Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men. 2013 , 26, 342-50	12	
257	Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial. 2013 , 127, 1200-8	56	
256	Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins. 2013 , 128, 365-76	98	
255	Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. <i>European Journal of Heart Failure</i> , 2013 , 15, 119-22	12.3	35

254	Erectile dysfunction in heart failure patients: a critical reappraisal. 2013 , 1, 177-91		16
253	Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects. <i>Circulation: Heart Failure</i> , 2013 , 6, 1268-83	7.6	19
252	Sildenafil increases sympathetically mediated vascular tone in humans. 2013 , 26, 762-9		12
251	Sildenafil and diastolic dysfunction after acute myocardial infarction trial: rationale and design. 2013 , 36, 179-83		
250	Transcriptional and post-transcriptional regulation of cGMP-dependent protein kinase (PKG-I): pathophysiological significance. 2013 , 97, 200-7		20
249	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. 2013 , 98, 1359-67		35
248	Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling. 2013 , 8, e58841		22
247	Effects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training. 2013 , 8, e69954		20
246	Vascular Pharmacology. 2013 , 75-93		1
245	Sildenafil improves clinical and functional status of an elderly postmenopausal female with 'out of proportion' PH associated with left heart disease. 2013 , 80, 193-4		
244	The Pathophysiology of Cardiac Hypertrophy and Heart Failure. 2014 , 51-78		13
243	Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. 2014 , 12, 185		58
242	PKG-1 β leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension. 2014 , 307, L537-44		14
241	Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system. 2014 , 19, 53-64		17
240	Echocardiographic assessment of pulmonary artery systolic pressure and outcomes in ambulatory heart failure patients. <i>Journal of the American Heart Association</i> , 2014 , 3, e000363	6	26
239	Lung capillary injury and repair in left heart disease: a new target for therapy?. 2014 , 127, 65-76		17
238	Herzinsuffizienz mit erhaltener LV-Funktion. 2014 , 10, 25-46		
237	Tadalafil prevents acute heart failure with reduced ejection fraction in mice. <i>Cardiovascular Drugs and Therapy</i> , 2014 , 28, 493-500	3.9	18

236	Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. 2014 , 76, 541-9		61
235	Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2014 , 16, 494-508	12.3	71
234	Riociguat for pulmonary hypertension. 2014 , 7, 259-70		6
233	Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2014 , 16, 444-53	12.3	19
232	Targeting cardiac hypertrophy: toward a causal heart failure therapy. 2014 , 64, 293-305		55
231	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. 2014 , 2014, 257-90		10
230	Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. 2014 , 70, 147-54		10
229	Targeting NOS as a therapeutic approach for heart failure. 2014 , 142, 306-15		37
228	Should there be sex-specific criteria for the diagnosis and treatment of heart failure?. 2014 , 7, 139-55		29
227	Abnormalities in cardiopulmonary exercise testing ventilatory parameters in heart failure: pathophysiology and clinical usefulness. 2014 , 11, 80-7		20
226	Treatment strategies for myocardial recovery in heart failure. 2014 , 16, 287		16
225	Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure. 2014 , 211, 314-33		12
224	Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. 2014 , 144, 12-27		89
223	Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction. 2014 , 11, 1101-15		28
222	New drugs and devices in the pipeline for heart failure with reduced ejection fraction versus heart failure with preserved ejection fraction. 2014 , 11, 374-81		4
221	Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond. 2014 , 35, 404-13		45
220	PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. 2014 , 172, 581-7		30
219	Ubiquitin-proteasome system and hereditary cardiomyopathies. 2014 , 71, 25-31		59

218	Clinical and molecular genetics of the phosphodiesterases (PDEs). 2014 , 35, 195-233		157
217	Re: Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. 2014 , 66, 175-6		3
216	Re: Global effects of smoking, of quitting, and of taxing tobacco. 2014 , 66, 176-8		4
215	.		
214	Intensive Care in Cardiac Failure. 2014 , 503-519		
213	An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine. 2014 , 145, 1383-1391		50
212	New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study. <i>European Journal of Heart Failure</i> , 2015 , 17, 680-8	12.3	56
211	Pulmonary hypertension in potential heart transplant recipients: current treatment strategies. 2015 , 20, 570-6		6
210	Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension. 2015 , 65, 640-8		7
209	Sildenafil Protects against Myocardial Ischemia-Reperfusion Injury Following Cardiac Arrest in a Porcine Model: Possible Role of the Renin-Angiotensin System. 2015 , 16, 27015-31		14
208	The emperor's new clothes: PDE5 and the heart. 2015 , 10, e0118664		26
207	Redox regulation of cGMP-dependent protein kinase II in the cardiovascular system. 2015 , 6, 139		18
206	Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?". 2015 , 7, 544-54		7
205	Inflammation in Heart Failure with Preserved Ejection Fraction. 2015 , 3-18		3
204	Treatment of Chronic Right Heart Failure. <i>Respiratory Medicine</i> , 2015 , 401-418	0.2	
203	Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. 2015 , 36, 2050-2060		89
202	Obesity in the ICU. 2015 , 787-795		
201	Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. 2015 , 172, 1397-414		21

200	Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. 2015 , 89, 1401-38		337
199	Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF. 2015 , 38, 829-39		11
198	Sildenafil in heart transplant candidates with pulmonary hypertension. 2015 , 108, 375-84		11
197	Exercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy. 2015 , 42, 50-4		1
196	Inhibition of type 5 phosphodiesterase counteracts β -adrenergic signalling in beating cardiomyocytes. 2015 , 106, 408-20		29
195	Right atrial volume and reservoir function are novel independent predictors of clinical worsening in patients with pulmonary hypertension. 2015 , 34, 414-23		34
194	PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial. 2015 , 169, 813-822.e3		31
193	[New therapy concepts for heart failure with preserved ejection fraction]. 2015 , 40, 194-205		1
192	Increased pulmonary vascular resistance, right ventricular dysfunction, and reversible pulmonary vasoconstriction in type 2 pulmonary hypertension: who has it and are we missing a potential therapeutic target in patients with heart failure?. <i>European Journal of Heart Failure</i> , 2015 , 17, 237-8	12.3	2
191	Hemodynamic response to sildenafil in patients with decompensated congestive heart failure can be predicted by deceleration time of transmitral flow. 2015 , 65, 72-9		
190	Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2015 , 8, 533-41	7.6	49
189	Cardiopulmonary Exercise Testing in Heart Failure. 2015 , 40, 322-72		46
188	The pathophysiology of pulmonary hypertension in left heart disease. 2015 , 309, L924-41		40
187	S-nitrosylation of PDE5 increases its ubiquitin-proteasomal degradation. 2015 , 86, 343-51		14
186	Molecular Screen Identifies Cardiac Myosin-Binding Protein-C as a Protein Kinase G-II β Substrate. <i>Circulation: Heart Failure</i> , 2015 , 8, 1115-22	7.6	25
185	Interventional Cardiology in the Elderly. 2015 ,		
184	Pulmonary hypertension in heart failure with preserved ejection fraction. 2015 , 34, 273-81		15
183	PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. 2015 , 147, 12-21		144

182	The Right Ventricle in Health and Disease. <i>Respiratory Medicine</i> , 2015 ,	0.2	4
181	Subclinical left ventricular deterioration in patients with erectile dysfunction. 2016 , 71, 557-563		3
180	Group 2 PH: Medical Therapy. 2016 , 59, 71-7		3
179	Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G II α Oxidation. 2016 , 291, 17427-36		34
178	Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. 2016 , 69, 1167.e1-1167.e85		91
177	PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial. 2016 , 101, 1525-34		30
176	Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective. 2016 , 109, 431-43		73
175	Coronary Heart Disease, Diabetes, and Sexuality in Men. 2016 , 13, 887-904		28
174	The Diagnostic Challenge of Group 2 Pulmonary Hypertension. 2016 , 59, 22-9		12
173	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2016 , 18, 891-975		775 ¹
172	Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial. <i>Circulation: Heart Failure</i> , 2016 , 9, e002729	7.6	53
171	Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact. 2016 , 17, 2281-2289		1
170	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2016 , 18, 891-975	12.3	4036
169	Nepriylsin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. 2016 , 41, 119-27		10
168	Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. 2016 , 17, 530		5
167	Medical Treatment of Aortic Stenosis. 2016 , 134, 1766-1784		62
166	Novel Therapeutic Targets of Pulmonary Hypertension. 2016 , 36, e97-e102		12
165	[Cyclic nucleotide phosphodiesterases: role in the heart and therapeutic perspectives]. 2016 , 210, 127-138		1

164	Methods for Evaluating Right Ventricular Function and Ventricular-Arterial Coupling. 2016 , 59, 42-51	22
163	Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum. 2016 , 68, 368-78	148
162	Sildenafil in heart failure with reactive pulmonary hypertension (Sildenafil HF) clinical trial (rationale and design). 2016 , 6, 161-7	6
161	Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. 2016 , 111, 154-62	32
160	Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy. 2016 , 39, 1238-52	31
159	Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury. 2016 , 356, 284-92	13
158	Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model. 2016 , 37, 473-82	14
157	New Diagnostic and Therapeutic Strategies for Pulmonary Hypertension Associated with Left Heart Disease. 2016 , 18, 18	
156	Swimming-Induced Pulmonary Edema: Pathophysiology and Risk Reduction With Sildenafil. 2016 , 133, 988-96	44
155	Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2016 , 5,	6 54
154	Treatment of pulmonary hypertension. 2016 , 4, 323-36	75
153	Update in treatment options in pulmonary hypertension. 2016 , 35, 695-703	18
152	From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. 2016 , 102, 320-30	17
151	New Pharmacological Strategies to Increase cGMP. 2016 , 67, 229-43	26
150	Pulmonary hypertension due to left heart disease: The prognostic implications of diastolic pulmonary vascular pressure gradient. 2016 , 67, 555-9	21
149	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. 2016 , 39, 131-42	18
148	Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. 2016 , 39, 143-51	22
147	Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors. 2017 , 5, 170-199	11

146	Phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction: trading therapy for prevention. <i>European Journal of Heart Failure</i> , 2017 , 19, 337-339	12.3	8
145	New pharmacological approaches in heart failure therapy: developments and possibilities. 2017 , 13, 173-188		
144	Impaired Right Heart and Pulmonary Vascular Function in HFpEF: Time for More Risk Markers?. 2017 , 10, 1222-1224		6
143	Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. 2017 , 17, 150		23
142	Manual of Gynecardiology. 2017 ,		0
141	The Graham Jackson Memorial Lecture ISSM 2016-"The Man Who Knew Too Much": Time to Recognize Erectile Dysfunction and Low Testosterone as Independent Risk Factors for Cardiovascular Disease. 2017 , 5, 256-265		11
140	Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7. 2017 , 7, 44584		24
139	Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation. 2017 , 188, 42-52		15
138	Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5). 2017 , 60, 486-496		5
137	Comparing the Efficacy of Tadalafil Versus Placebo on Pulmonary Artery Systolic Pressure and Right Ventricular Function in Patients with Beta-Thalassaemia Intermedia. 2017 , 26, 677-683		7
136	Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment. 2017 , 14, 519-528		30
135	Signalling Microdomains: The Beta-3 Adrenergic Receptor/NOS Signalingosome. 2017 , 215-244		
134	Management of combined pre- and post-capillary pulmonary hypertension in advanced heart failure with reduced ejection fraction. 2017 , 131, 94-100		1
133	Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis. 2017 , 9, 123-135		2
132	Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball. 2017 , 19, 70		18
131	Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases. 2017 , 57, 455-479		61
130	Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment. 2017 , 23, 72-80		22
129	Sex Differences in Metabolic Cardiomyopathy. 2017 , 113, 370-377		26

128	Accuracy of echocardiographic indices for serial monitoring of right ventricular systolic function in patients with precapillary pulmonary hypertension. 2017 , 12, e0187806		5
127	Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration. 2017 , 79, 788-794		4
126	Phosphodiesterase type 5 and cancers: progress and challenges. 2017 , 8, 99179-99202		28
125	Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle. 2018 , 114, 782-793		30
124	Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. 2018 , 15, 44-52		9
123	Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?. 2018 , 104, 1244-1250		43
122	MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A. 2018 , 36, 1847-1857		21
121	Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. 2018 , 137, e578-e622		264
120	Erectile dysfunction and testosterone deficiency as cardiovascular risk factors?. 2018 , 72, e13054		6
119	Nitric oxide signalling in cardiovascular health and disease. 2018 , 15, 292-316		259
118	British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Men-2017. 2018 , 15, 430-457		67
117	Exploring New Cardiovascular Pathways: Are Soluble Guanylate Cyclase Stimulators the Right Direction?. <i>Circulation: Heart Failure</i> , 2018 , 11, e004813	7.6	5
116	Prevention of PKG-1 α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation. <i>Circulation: Heart Failure</i> , 2018 , 11, e004740	7.6	17
115	Cardiac unloading by LVAD support differentially influences components of the cGMP-PKG signaling pathway in ischemic and dilated cardiomyopathy. 2018 , 33, 948-957		4
114	Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction. 2018 , 314, H170-H179		7
113	Heart failure with preserved ejection fraction: current management and future strategies : Expert opinion on the behalf of the Nucleus of the "Heart Failure Working Group" of the German Society of Cardiology (DKG). 2018 , 107, 1-19		57
112	Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. 2018 , 137, 1796-1810		130
111	Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V. 2018 , 43, 217-231		1

110	Heart Transplantation for Adult Congenital Heart Disease: Overview and Special Considerations. 2018 , 3, 73-84	1
109	Targeted HFpEF therapy based on matchmaking of human and animal models. 2018 , 315, H1670-H1683	8
108	Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis. 2018 , 13, e0204610	7
107	Pulmonary Hypertension: Good Intentions, But a Questionable Approach. 2018 , 15, 664-666	3
106	Heart Failure: Influence of Drug Interventions on Vessels. 2018 , 575-588	
105	Pulmonary Hypertension and Heart Failure: A Dangerous Liaison. 2018 , 14, 297-309	10
104	Effect of heart rate reduction in pulmonary arterial hypertension. 2018 , 314, H889-H891	1
103	Helping to understand heart failure with preserved ejection fraction. 2018 , 39, 2836-2838	2
102	Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure. 2018 , 115, E7428-E7437	24
101	Sildenafil ameliorates right ventricular early molecular derangement during left ventricular pressure overload. 2018 , 13, e0195528	9
100	Acute stimulation of the soluble guanylate cyclase does not impact on left ventricular capacitance in normal and hypertrophied porcine hearts in vivo. 2018 , 315, H669-H680	5
99	An update on the drug safety of treating erectile dysfunction. 2019 , 18, 965-975	6
98	Pulmonary Hypertension in Advanced Heart Failure: Assessment and Management of the Failing RV and LV. 2019 , 16, 119-129	2
97	The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure. 2019 , 8,	15
96	Heart Failure With Preserved Ejection Fraction: Is Ischemia Due to Coronary Microvascular Dysfunction a Mechanistic Factor?. 2019 , 132, 692-697	19
95	Phosphodiesterase-5 Inhibitor Therapy and Post-Left Ventricular Assist Device Outcomes. <i>Circulation: Heart Failure</i> , 2019 , 12, e006162	7.6 1
94	Challenges in pulmonary hypertension associated with left heart disease. 2019 , 17, 461-472	1
93	Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure. 2019 , 9, 6801	22

92	Cardiac Remodeling: The Course Towards Heart Failure-II. Diagnostic and Therapeutic Approaches. 2019 , 247-280		
91	Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome?. 2019 , 7, 192-203		23
90	Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease. 2019 , 33, 462-470		1
89	Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. 2019 , 73, 195-205		3
88	Dehydroepiandrosterone attenuates pulmonary artery and right ventricular remodeling in a rat model of pulmonary hypertension due to left heart failure. <i>Life Sciences</i> , 2019 , 219, 82-89	6.8	4
87	Treatment of Heart Failure with Preserved Ejection Fraction. 2020 , 568-585		
86	Icariin attenuates isoproterenol-induced cardiac toxicity in Wistar rats via modulating cGMP level and NF- κ B signaling cascade. 2020 , 39, 117-126		7
85	cGMP Signaling and Modulation in Heart Failure. 2020 , 75, 385-398		11
84	Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. 2020 , 76, 1795-1807		26
83	Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review. 2020 , 10, 2045894020948780 ²		
82	PDE5 Inhibitors in Type 2 Diabetes Cardiovascular Complications. 2020 , 1, 90-101		2
81	Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy. 2020 , 75, 1397-1408		21
80	Comparative therapeutic effect of the L-arginine and sildenafil on beta-thalassemia children with increased tricuspid regurgitant jet velocity. 2020 , 5, 25-29		1
79	Pulmonary vascular resistance as a potential marker of reactive pulmonary hypertension reduction following sildenafil therapy in patients disqualified from orthotopic heart transplantation. 2020 , 65, 298-303		
78	Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2020 , 34, 401-417	3.9	7
77	Estrogen Receptor- α Non-Nuclear Signaling Confers Cardioprotection and is Essential to cGMP-PDE5 Inhibition Efficacy. 2020 , 5, 282-295		11
76	Muscarinic-dependent phosphorylation of the cardiac ryanodine receptor by protein kinase G is mediated by PI3K-AKT-nNOS signaling. 2020 , 295, 11720-11728		2
75	Full Issue PDF. 2020 , 5, I-CVIII		

74	Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?. 2020 , 208, 107475	17
73	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. 2020 , 109, 1079-1098	41
72	Effect of sildenafil on right ventricular performance in an experimental large-animal model of postcapillary pulmonary hypertension. 2021 , 228, 64-75	1
71	An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases. 2021 , 16, 183-196	3
70	Pulmonary Hypertension Due to Left Heart Disease-A Practical Approach to Diagnosis and Management. 2021 , 37, 572-584	4
69	Future Therapies in HFpEF. 2021 , 489-494	
68	Erectile Dysfunction and Cardiovascular Risk in Men With Rheumatoid Arthritis: A Population-based Cohort Study. 2021 , 48, 1641-1647	2
67	Myocardial Impact of NHE1 Regulation by Sildenafil. 2021 , 8, 617519	0
66	Intensive care management of right ventricular failure and pulmonary hypertension crises. 2021 , 56, 636-648	3
65	Pulmonary vasodilator use in continuous-flow left ventricular assist device management. 2021 , 9, 522	
64	Alternative strategies in cardiac preclinical research and new clinical trial formats. 2021 ,	3
63	Combined pre- and post-capillary pulmonary hypertension: The clinical implications for patients with heart failure. 2021 , 16, e0247987	3
62	Clinical and hemodynamic effects of oral sildenafil on biventricular function on patients with left ventricular systolic dysfunction. 2021 , 75, e14171	0
61	Heart failure with preserved ejection fraction based on aging and comorbidities. 2021 , 19, 291	1
60	Cyclic GMP modulating drugs in cardiovascular diseases: Mechanism-based network pharmacology. 2021 ,	1
59	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. 2021 , e3494	6
58	PDE5 Inhibition Suppresses Ventricular Arrhythmias by Reducing SR Ca Content. 2021 , 129, 650-665	2
57	Right ventricular function as assessed by cardiac magnetic resonance imaging-derived strain parameters compared to high-fidelity micromanometer catheter measurements. 2021 , 11, 2045894021103252 ¹	

56	Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities. 2021 , 226, 107858		2
55	CRD-733, a Novel PDE9 (Phosphodiesterase 9) Inhibitor, Reverses Pressure Overload-Induced Heart Failure. <i>Circulation: Heart Failure</i> , 2021 , 14, e007300	7.6	6
54	Cyclic Nucleotide Phosphodiesterases and Compartmentation in Normal and Diseased Heart. 2017 , 97-116		1
53	PDE5 inhibitor efficacy is estrogen dependent in female heart disease. 2014 , 124, 2464-71		49
52	Sex, drugs, and trial design: sex influences the heart and drug responses. 2014 , 124, 2375-7		10
51	The Effects and Mechanism of Atorvastatin on Pulmonary Hypertension Due to Left Heart Disease. 2016 , 11, e0157171		14
50	Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis. 2017 , 9, 488-498		21
49	Pulmonary Hypertension in Heart Failure Patients. 2020 , 6, e05		2
48	Breakthrough in heart failure with preserved ejection fraction: are we there yet?. 2016 , 31, 1-14		10
47	Endothelial function and atrial fibrillation: A missing piece of the puzzle?. 2021 ,		2
46	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	1
45	Clinical Trials Update. 2011 , 10, 60-61		
44	H. 2013 , 447-566		
43	Right Heart Failure. 2014 , 311-329		
42	Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension. <i>Arquivos Brasileiros De Cardiologia</i> , 2015 , 104, 85-9	1.2	2
41	Aging and Right Ventricular Failure from Pulmonary Hypertension: Effect of Right Ventricular and Pulmonary Artery Remodeling. 2014 , 291-304		
40	The Right Ventricle in Left Heart Failure. <i>Respiratory Medicine</i> , 2015 , 361-390		0.2
39	Pulmonary Hypertension in the Elderly: Impact of Age on Diagnosis and Therapy Options. 2015 , 109-133		

38	New therapy approach in heart failure with preserved ejection fraction based on new pathophysiological concept. <i>Srce I Krvni Sudovi</i> , 2016 , 35, 53-59		
37	Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension. 2016 , 29-61		
36	Heart Failure in Women: Is There a Typical Female Type?. 2017 , 107-116		
35	PDE5 inhibition improves symptom-free survival and restores transverse tubule loss and catecholamine responsiveness in heart failure.		
34	Aging male and its complications - erectile dysfunction and testosterone deficiency syndrome. <i>Medicína Pro Praxi</i> , 2018 , 15, 103-106	0	
33	Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. <i>Current Vascular Pharmacology</i> , 2021 , 19, 301-312	3.3	2
32	Novel treatments for diastolic heart failure. 2020 , 95-127		
31	Phosphodiesterase-5 inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2013 , 218, 229-55	3.2	2
30	Underrated value of repeated right heart catheterization in pulmonary hypertension with heart failure-a case of persisted pulmonary arterial hypertension after treatment for biventricular failure. <i>Journal of Thoracic Disease</i> , 2015 , 7, E489-92	2.6	
29	The mitochondrial regulator PGC1 β s induced by cGMP-PKG signaling and mediates the protective effects of phosphodiesterase 5 inhibition in heart failure. <i>FEBS Letters</i> , 2021 , 596, 17	3.8	4
28	Effects of phosphodiesterase 5 inhibition on cardiovascular function in resistant hypertension: A systematic review.. <i>Life Sciences</i> , 2022 , 291, 120270	6.8	
27	Heart Failure. 2022 , 103-155		
26	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update.. <i>Cardiovascular Drugs and Therapy</i> , 2022 , 1	3.9	1
25	Cardiorenal Effects of Long-Term Phosphodiesterase V Inhibition in Pre-Heart Failure.. <i>Journal of the American Heart Association</i> , 2022 , e022126	6	
24	The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	2
23	Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies.. <i>Biomedicines</i> , 2022 , 10,	4.8	3
22	Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (The SilHF study): A randomised placebo-controlled multicentre trial. <i>European Journal of Heart Failure</i> ,	12.3	1
21	Hemodynamic Response to Acute Volume Load and Endomyocardial NO-synthase Gene Expression in Heart Transplant Recipients. <i>Transplantation Direct</i> , 2022 , 8, e1336	2.3	

20	New Possibilities in Heart Failure: The Effects of Tadalafil on Diastolic Function in Patients Undergoing Robot-Assisted Radical Prostatectomy. <i>Applied Sciences (Switzerland)</i> , 2022 , 12, 5629	2.6	0
19	ROCK and PDE-5 Inhibitors for the Treatment of Dementia: Literature Review and Meta-Analysis. <i>Biomedicines</i> , 2022 , 10, 1348	4.8	1
18	Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. <i>Science Translational Medicine</i> , 2022 , 14,	17.5	1
17	Moving beyond the Vasodilator Model in Heart Failure with reduced Ejection Fraction - Lessons from Sildenafil. <i>European Journal of Heart Failure</i> ,	12.3	
16	Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors. 2022 , 15, 1024		
15	Pulmonary vascular causes of complex breathlessness: exercise pulmonary hypertension, pulmonary veno-occlusive disease and pre-load failure. 2022 , 140-152		
14	Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.		1
13	Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. 2023 , 63,		1
12	The efficacy of PDE5 inhibitors in diabetic patients.		2
11	Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants. 2022 , 15,		0
10	How to Treat Right Heart Failure. Tips for Clinicians in Everyday Practice. 2023 , 19, 125-135		0
9	The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies. 2022 , 0		0
8	Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics. 9,		1
7	β adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial.		2
6	Phosphodiesterase 5 Inhibitor Potentiates Epigallocatechin 3-O-Gallate-Induced Apoptotic Cell Death via Activation of the cGMP Signaling Pathway in Caco-2 Cells. 2022 , 44, 6247-6256		0
5	Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential.		0
4	New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside and Back. 2023 , 11, 70		0
3	Intravenous sildenafil for treatment of early and late pulmonary hypertension in preterm infants.		0

- 2 Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease. ○
- 1 Heart failure therapy: the fifth card. **2023**, 25, B140-B143 ○